莫西沙星与左氧氟沙星治疗社区获得性肺炎的临床研究  

The Clinical stady of moxifloxacin and levofloxacin in the treatment of community-acquired pneumonia for the treatment community-acquired pneumonia

作　　者：曾峰[1] 林雅[1] 肖靖华[1] 廖美玲[1] 

机构地区：[1]暨南大学医学院第五附属医院清远市人民医院,广东清远511500

出　　处：《临床肺科杂志》2011年第11期1667-1668,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨莫西沙星和左氧氟沙星治疗社区获得性肺炎的疗效。方法选择社区获得性肺炎患者120例,随机分成莫西沙星组60例和左氧氟沙星组60例,分别给予治疗7 d,运用药物经济学的成本-效果分析方法进行评价。结果莫西沙星组和左氧氟沙星组治疗有效率分别为98.33%和71.67%,细菌清除率分别为91.67和65.57%,不良反应发生率分别为8.33%和13.33%,成本-效果比分别为21.87%和10.26%。结论莫西沙星组的治疗有效率和细菌清除率明显优于左氧氟沙星组(P<0.01),莫西沙星治疗社区获得性肺炎在临床治疗中是优选方案。Objective To study the clinical Value in moxifloxacin and levofloxacin for the treatment of community-acquired pneumonia（CAP）.Methods 120 patients of CAP were chosen and divided randomly into team of moxifloxacin and team of levofloxacin.These two categories of patients were given separate treatments for 7 days which were analyzed and appraised by the cost-effect method in pharmacoeconomic research.Results The Overall clinical effective rate for team of moxifloxacin was 98.33% and for team of levofloxcine was 71.67%;the bacterial clearance rate for team of moxifloxacin was 91.67% and for team of levofloxcine was 65.57%;Occurrence of the adverse reaction for team moxifloxacin was 8.33% and for team levofloxcine was 13.33%,and the cost-effectiveness ratios were 21.87 and 10.26.Conclusion The overall clinical effective rate and the bacterial clearance rate of team moxifloxacin is better than that of team levofloxcine.Moxifloxacin for the treatment CAP is the preferred plan in the clinic.

关 键 词：莫西沙星 左氧氟沙星 社区获得性肺炎 成本-效果分析 

分 类 号：R563.1[医药卫生—呼吸系统]